Navigation Links
Derma Sciences Announces Commercial Launch of XTRASORB(TM)
Date:10/21/2008

Novel polymer-based super-absorbent dressing will be first of its kind in

US and Canada

PRINCETON, N.J., Oct. 21 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a company specializing in advanced wound care, today announced the commercial launch of its newest product -- XTRASORB(TM) Super Absorbent Dressing. The novel dressing features a polymer-based core that could help change the way clinicians manage heavily exuding wounds, currently a significant issue in wound care. The dressing will be launched at next week's Clinical Symposium on Advances in Skin & Wound Care in Las Vegas.

Commenting on the launch, CEO Ed Quilty stated, "This is something we have been excited about for quite a while. Foam dressings, for highly exuding wounds, is the single largest category of moist wound dressings, with over $300 million in global sales. Still, even the best dressings in this category have limitations. Clinicians still want dressings to hold more fluid to reduce the number of time-consuming and costly dressing changes. Additionally, the fluid that a foam dressing does absorb is at a high risk of being pushed back onto the wound bed, potentially causing serious complications to the wound. For these reasons, our market research shows that clinicians will love the fact that XTRASORB can absorb roughly 50% more than even the most absorbent foam dressing, and that the polymer-based super-absorbent core forms a gel which locks all the wound fluid inside the dressing and away from the wound. This has multiple benefits, including reducing the risk of wound breakdown due to excessive moisture, as well as keeping harmful bacteria often found in wound fluid away from the wound."

Quilty continued, "Based on our research and feedback from customers, we are extremely confident that we will have another successful product launch. We launched MEDIHONEY(R) Dressings last year at the Clinical Symposium, and we have done very well with that product. Our expectations for XTRASORB are very high, and we look forward to it being a significant contributor to our overall growth moving forward. This is yet another step in the course we've charted out over the past several years -- using the cash flow from our $50+ million revenue baseline business to fund the development of novel higher margin advanced wound care products, and then to launch and support them with marketing and our growing sales organization. This is what is going to drive our topline growth and profitability."

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from The University of Southern California in Q4 of 2007 and is entering into a Phase II study, with anticipated initial patient enrollment to begin in Q3 of 2008. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

Contact: Derma Sciences, Inc. Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO r.barrio@allencaron.com

equilty@dermasciences.com

(609) 514-4744 Brian Kennedy (media)

brian@allencaron.com

(212) 691-8087


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
2. Age Spots Are No Match for Cosmetic Dermatology Treatments
3. Dermatologists Score Healthy First for Fans at Final Tennis Tournament Before U.S. Open
4. Watson Announces Limited Recall of Fentanyl Transdermal System
5. Derma Sciences Conference Call Advisory
6. American Academy of Dermatology: Dermatologists Warn Ceramic Flat Irons Could Damage Hair and Lead to Hair Breakage
7. American Academy of Dermatology: Acne and Rosacea Got You Seeing Red? Patients with Skin of Color Advised to Seek Proper Diagnosis, Treatment to Prevent Common Side Effects
8. Galderma announces approval for Differin gel 0.1 percent in Japan
9. Dermatologists In Denial: Controversial New Chocolate Nutraceutical Claims to be Good for Your Skin
10. 4th Annual Dermatology Nurses Association Summer Meeting to Arrive in Windy City
11. Derma Sciences Launches Two New MEDIHONEY(TM) Formulations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... coffee house-caliber protein espresso drinks, announced its products are now available for purchase ... Coffee Protein Drink Mix has become popular among health-conscious consumers who love coffee ...
(Date:2/20/2017)... ... February 21, 2017 , ... Nancy Johnston Toll ... a way to “ Getting Over the Bump in the Road ” (published by ... learned on how to cope with the ups and downs experienced by anyone going ...
(Date:2/20/2017)... Orlando, FL (PRWEB) , ... February 20, 2017 ... ... Director, beth[at]orbitahealth[dot]com, +1 (414) 213-8818 , Orbita, Inc., a leading provider of innovative ... software-as-a-service solution for increasing patient engagement and optimizing care journey management for home ...
(Date:2/20/2017)... ... 20, 2017 , ... Today, Biscom , the leader ... first IoT device from Biscom designed to deliver confidential patient information securely and ... HIMSS17 and will be conducting demonstrations at Booth #374. , ...
(Date:2/20/2017)... Houston, TX (PRWEB) , ... February 20, 2017 ... ... he is now offering a full range of emergency dental care at his ... teeth and gums. When patients experience dental emergencies, they are at risk for ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... 2017 Mass Spectrometer Market: Overview ... This report on mass spectrometer market ... of the market globally. The stakeholders of this ... manufacture and commercialization of various mass spectrometer instrument ... to enter this market. This report comprises an ...
(Date:2/21/2017)... , Feb. 21, 2017  Luminex Corporation (NASDAQ: ... directors has authorized the initiation of a quarterly cash dividend ... initial cash dividend will be payable on April 14, 2017 ... on March 24, 2017. The board of ... cash dividend of $0.06 to holders of its common stock, ...
(Date:2/21/2017)... , Feb. 21, 2017  Global health services company ... Dermacell ® for breast reconstruction surgery and ... is an advanced acellular dermal matrix developed by LifeNet ... NVDQ ) "We are ... commercial health-care payers to review the growing base of ...
Breaking Medicine Technology: